Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio
Immorta Bio Inc. has announced the publication of its international patent application for SenoVaxTM, a novel senolytic immunotherapy aimed at combating the underlying causes of aging and cancer. The announcement was made on November 25, 2025, in Miami Beach, Florida, marking a significant advancement in the field of longevity therapy.
The patent application, identified as PCT/WO2025184665, details a proprietary method to stimulate the immune system to target and eliminate senescent cells—cells that contribute to aging, inflammation, and tumor growth. By effectively removing these detrimental cells, SenoVaxTM has shown a potential for producing broad anti-aging effects while simultaneously inhibiting cancer progression.
At the heart of the patent is SenoVaxTM, which has demonstrated significant efficacy in reducing various cancers, including lung, breast, brain, skin, and pancreatic cancers, in established in vivo models. The therapy is also currently under review by the U.S. Food and Drug Administration (FDA) following the submission of Investigational New Drug (IND) application #30745 for advanced lung cancer treatment.
Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio, emphasized the unique nature of SenoVaxTM, stating, “By killing senescent cells, we reduce aging biology itself while simultaneously disrupting the tumor-supportive microenvironment required for cancer survival.” This dual action positions SenoVaxTM as a pioneering solution in the fight against age-related diseases.
Immorta Bio’s broader strategy for longevity includes the integration of SenoVaxTM with another innovative platform, StemCellRevivifyTM. This approach utilizes young, organ-specific progenitor and mesenchymal stem cells to restore the body’s regenerative capabilities. Together, these platforms address two critical factors of aging: the impaired clearance of damaged cells and the decline of tissue regeneration.
Dr. Boris Reznik, Chairman and CEO of Immorta Bio, pointed out the relevance of this research, stating, “Cancer is the most prevalent disease of aging, and SenoVaxTM allows us to attack both aging biology and tumor biology at the same time.” The company aims to establish the safety and efficacy of SenoVaxTM in advanced cancer patients, with plans to expand its applications to age-related conditions and ultimately to the treatment of aging itself.
Preclinical studies conducted by Immorta Bio have shown compelling results, including improvements across multiple cancer models, aging and frailty models, and organ-failure models. Notably, the research indicates more than 100% extension of lifespan and enhancement of healthspan, reinforcing the company’s mission to develop a comprehensive solution for age-related diseases.
As Immorta Bio continues to advance its research and development efforts, the publication of the PCT application strengthens its position as a leader in creating a dual-platform approach to aging that also targets its most critical diseases.
For more information about Immorta Bio, their ongoing research, and the innovative therapies they are developing, visit their website at www.ImmortaBio.com or contact their media team at +1 (305) 632-2939.
